Opexa Therapeutics, Inc.

Genexine Inc. , established more than 20 years ago, has now reached a juncture where it needs significant changes in strategy to move forward towards its ambition of become a leading global biopharma

Financings Third-quarter 2017 biopharma financing reached $12.5 billion, just a 6% decrease from the previous quarter's $13.4 billion. ( See Exhibit 1. ) The most money was raised in the follow-on pub

IN VITRO DIAGNOSTICS Alliances Angle PLC Qiagen NV Angle PLC and Qiagen NV will co-promote each other’s liquid biopsy solutions for cancer detection. (Sep.) To the deal Angle contributes its

Biopharmaceutical start-up companies – firms founded four years ago or less – raised fewer dollars during the third quarter than during the prior quarter despite Roivant Sciences GMBH 's massive $1